OCTASIC-INC
17.9.2020 04:02:10 CEST | Business Wire | Press release
Panasonic Corporation, a world-leading provider of diverse electronics technologies, B2B, communications and wireless solutions, and Octasic Inc., an innovation leader in low-power programmable processors for wireless and multimedia applications, today announced the enhancement of their ongoing collaboration to develop shared eXtended Global Platform (sXGP) solutions to include 5G and Beyond 5G based wireless network products, especially for mission-critical applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005982/en/
Panasonic and Octasic will combine resources and expertise to develop high-performance, high reliability, and low-latency Small Cell solutions for the cellular IoT space, applied to B2B, Non-Terrestrial Networks in Avionics and other mission-critical verticals based on Octasic's OCT3032 System-on-Chip.
The Collaboration on sXGP
Panasonic has developed an sXGP wireless base station that makes full use of the OCT3032's embedded Opus DSP technology and realizes stable communication even in environments with high interference in unlicensed bands.
The 5G Collaboration
The expanded collaboration addresses the challenging requirements of developing a new class of Small Cells to be deployed in a wireless base station platform that contributes to mission-critical applications for advanced IoT environments and non-terrestrial operations toward 5G and Beyond 5G.
Octasic’s programmable processor platform delivers on the low power requirements of Panasonic Small Cell designs and accelerates development and support of multiple air interfaces from sXGP to 3GPP. More importantly it addresses the need for deterministic air interface design to meet the challenges of implementing an ultra-reliable low-latency solution in diverse environments from private campus-wide networks, to machine or robotic communication in warehouses, to aircraft systems.
Panasonic promotes the development of Ultra-Reliable and Low-Latency Communications (URLLC) functions that comply with both 3GPP and Non-Terrestrial Network (NTN) technologies and provides Octasic with engineering expertise and resources. In addition, Panasonic will accelerate digital transformation for itself and its customers demonstrating various IoT-related applications inside and outside the company.
Hideo Ohara, Director of Panasonic Technology Department, emphasized, “We are leveraging Octasic’s OCT3032 System-on-Chip, development tools, and 4G/5G software to develop and deploy differentiated sXGP, 4G, and 5G Small Cell network products that deliver on our world-leading technical requirements for high performance, highly reliable, low latency, and low power Small Cell network products. We are delighted to advance the evolution of society with such unique systems that are the culmination of our years of technological collaboration with Octasic.”
Fabio Gambacorta, Global VP Business Development and Sales at Octasic emphasized, “Offering a world-leading System-on-Chip solution for Small Cell designs does not happen by chance; it is critical to partner with an innovative wireless network OEM like Panasonic. Octasic is proud to collaborate on not only the development of Panasonic’s first sXGP network products, but to expand this collaboration to encompass future solutions for 3GPP-compliant 4G and 5G networks, especially those requiring high reliability, low latency, and low power.”
For more information about the OCT3032 SoC and its evaluation and development platforms, please contact pr@octasic.com or visit www.octasic.com/product/oct3032w/ .
About Octasic Inc.
Founded in 1998 and headquartered in Canada, Octasic develops innovative programmable processors for mobile wireless markets such as proprietary 4G/5G-based networks. Octasic’s Opus-based processor technology, programming tools, software and reference code reduce costs, mitigate risk, accelerate time-to-market, and allow developers to focus engineering resources on their areas of differentiation. With 20 years of technology development in low-power programmable System-on-Chip solutions, Octasic products deliver a low-power, low-latency “5G Small Cell on a Chip” for both commercial and private networks. For more information, please visit http://www.octasic.com/ .
About Panasonic Corporation
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 72 associated companies worldwide, recording consolidated net sales of 7.49 trillion yen for the year ended March 31, 2020. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global .
For media inquiries, please contact Global Communications Department:
https://news.panasonic.com/global/contacts/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005982/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
